Study of the efficacy of tadalafil combined with tamsulosin compared with tamsulosin alone in the management of lower urinary tract symptoms associated with benign prostatic hypertrophy
Abstract
* The importance and justification of the research:
Benign prostatic hyperplasia is one of the most common diseases associated with symptoms of the lower urinary tract, as these symptoms appear in 50% of men over 50 years of age.
. Treatment options range from drug therapies to invasive procedures
Recently, it has been suggested to add tadalafil (5 mg) to tamsulosin (0.4 mg) for 3 months as one of the available options for relieving associated lower urinary tract symptoms.
The need to find an effective treatment for patients with benign prostatic hyperplasia and the results of international studies, which were directed mostly to the safety and effectiveness of the participation of tadalafil 5 mg and tamsulosin 0.4 mg for a period of 3 months in treatment, and since no local study was previously conducted that shows the effectiveness of this participation, we directed to conduct this study
* The Aim:
Comparison of the effectiveness of a drug combination between tamsulosin 0.4 mg with tadalafil 5 mg and tamsulosin 0.4 mg alone in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia according to the International Scale of Prostate Symptoms
* Patients and methods:
Study type: prospective pilot study
The research sample consisted of (100) patients who attended the Urology Department and Clinic from 28/4/2022 to 28/ 4/2023
The patients' ages exceeded (50) years, and the patients were divided into two groups, and each group consisted of (50) patients
Pharmacotherapy (Tamsulosin) was applied only to the patients of the first group, and the drug treatment (Tamsulosin and Tadalafil) was applied to the patients of the second group. The first evaluation was done after (6) weeks and a final evaluation after (12) weeks.
* Results:
- The quality of life and the mean value of the quality of life index improved, and the degree of complaint decreased by continuing the combined treatment.
- In combination therapy, the rate of improvement is better, especially if the prostate was smaller before treatment
- In co-treatment, the percentage of improvement increases if the treatment period is increased
- In co-treatment, the rate of improvement is higher if the complaint was of medium degree before starting treatment.
*Recommendations and Suggestions:
Conducting a survey and early investigation of cases of symptomatic benign prostatic hypertrophy and treating them to avoid exacerbation of symptoms and lack of bladder compliance As a result, the upper urinary tract is damaged
Combination therapy of tamsulosin and tadalafil for benign prostatic hyperplasia with moderate to severe complaints
Emphasis on continuing treatment for 12 weeks and not interrupting it to achieve the best improvement
Periodic follow-up of co-treatment patients to assess the extent of benefit and improvement of symptoms
Conducting more studies and research related to healthy prostate enlargement to reach the best standards and recommendations aimed at controlling symptoms and improving patients’ quality of life.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.